Skip to main content
OpenTrials

Clinical trial condition

Recurrence

Explore clinical trials studying Recurrence. Study availability and eligibility vary by location and protocol.

2,312 public trials 521 recruiting studies
Refine in advanced search Browse all conditions

Recurrence trial results

Completed

A Study Evaluating the Safety and Efficacy of Brexucabtagene Autoleucel (KTE-X19) in Adult Subjects With Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia (ZUMA-3)

NCT02614066

Conditions
Disease Attributes, Pathologic Processes, Pathological Conditions, Signs and Symptoms, +2 more
Locations
  • UC San Diego-Moores Cancer Center La Jolla, California, United States
  • University of California Los Angeles (UCLA) Los Angeles, California, United States
  • University of California Irvine Medical Center Orange, California, United States
  • University of California Davis Comprehensive Cancer Center Sacramento, California, United States
View all 33 locations
View Trial Details
Completed

Investigating the Safety and Efficacy of Rituximab and Pembrolizumab in Relapsed/Refractory Waldenström's Macroglobulinaemia

NCT03630042

Conditions
Blood Protein Disorders, Cardiovascular Diseases, Disease Attributes, +17 more
Locations
  • Derriford Hospital, Univeristy Hospitals Plymouth NHS Trust Plymouth, Devon, United Kingdom
  • Torbay and South Devon NHS Foundation Trust Torquay, Devon, United Kingdom
  • Royal Bournemouth Hospital, University Hospitals Dorset NHS Foundation Trust Bournemouth, Dorset, United Kingdom
  • St Bartholomew's Hospital, Barts Health NHS Trust London, Greater London, United Kingdom
View Trial Details
Completed

Study of BGB-A317 in Participants With Relapsed or Refractory Mature T- and NK-cell Neoplasms

NCT03493451

Conditions
ALK-Positive Anaplastic Large Cell Lymphoma, ALK-negative Anaplastic Large Cell Lymphoma, Adult Nasal Type Extranodal NK/T-cell Lymphoma, +36 more
Locations
  • British Columbia Cancer Agency the Vancouver Centre Vancouver, British Columbia, Canada
  • Peking University Third Hospital Beijing, Beijing Municipality, China
  • Beijing Hospital Beijing, Beijing Municipality, China
  • Peking Union Medical College Hospital Beijing, Beijing Municipality, China
View all 24 locations
View Trial Details
Completed

Efficacy and Safety of Zanubrutinib in Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

NCT03206918

Conditions
Chronic Disease, Disease Attributes, Hematologic Diseases, +16 more
Locations
  • Peking University Peoples Hospital Beijing, Beijing Municipality, China
  • Peking Union Medical College Hospital Beijing, Beijing Municipality, China
  • Fujian Medical University Union Hospital Fuzhou, Fujian, China
  • Nanfang Hospital of Southern Medical University Guangzhou, Guangdong, China
View Trial Details
Completed

Study of BTK Inhibitor Zanubrutinib in Participants With Relapsed/Refractory Non-GCB Type Diffuse Large B Cell Lymphoma

NCT03145064

Conditions
Diffuse Large B-cell Lymphoma, Disease Attributes, Hemic and Lymphatic Diseases, +13 more
Locations
  • Beijing Cancer Hospital Beijing, Beijing Municipality, China
  • Harbin Medical University Cancer Hospital Harbin, Heilongjiang, China
  • Henan Cancer Hospital Zhengzhou, Henan, China
  • The First Affiliated Hospital of Soochow University Branch Shizi Suzhou, Jiangsu, China
View Trial Details

Related conditions